Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.

Berkhout LC, l'Ami MJ, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2019 Nov 19. pii: annrheumdis-2019-216557. doi: 10.1136/annrheumdis-2019-216557. [Epub ahead of print] No abstract available.

PMID:
31744825
2.

The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.

Berkhout LC, l'Ami MJ, Krieckaert CLM, Vogelzang EH, Kos D, Nurmohamed MT, Wolbink GJ, Rispens T.

Rheumatology (Oxford). 2019 Nov 6. pii: kez513. doi: 10.1093/rheumatology/kez513. [Epub ahead of print]

PMID:
31691828
3.

The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.

Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T.

Clin Exp Rheumatol. 2019 Aug 30. [Epub ahead of print]

PMID:
31498069
4.

Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.

Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS.

Expert Rev Clin Immunol. 2019 Aug;15(8):837-848. doi: 10.1080/1744666X.2019.1630273. Epub 2019 Jun 14.

PMID:
31180729
5.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2019 May 9. pii: annrheumdis-2019-215609. doi: 10.1136/annrheumdis-2019-215609. [Epub ahead of print] No abstract available.

PMID:
31072816
6.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

7.

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.

L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ.

Scand J Rheumatol. 2019 Jul;48(4):266-270. doi: 10.1080/03009742.2019.1577915. Epub 2019 Apr 23.

PMID:
31012365
8.

Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.

Ruwaard J, Marsman AF, Nurmohamed MT, van der Horst-Bruinsma IE, Te Velthuis H, Bloem K, de Vries A, Rispens T, Wolbink G.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):756-761. Epub 2019 Mar 18.

9.

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A.

Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3.

10.

Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Layegh Z, Ruwaard J, Hebing RCF, L' Ami MJ, van der Weele W, Nurmohamed MT, Krieckaert C, Wolbink G.

Int J Rheum Dis. 2019 May;22(5):869-873. doi: 10.1111/1756-185X.13512. Epub 2019 Feb 14.

PMID:
30767391
11.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T.

Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

PMID:
30700574
12.

Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy.

Ruwaard J, VAN DER Vlugt ER, Wolbink G.

J Rheumatol. 2019 Jan;46(1):117-118. doi: 10.3899/jrheum.180566. Epub 2018 Oct 15. No abstract available.

PMID:
30323005
13.

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.

Vogelzang EH, Hebing RCF, Nurmohamed MT, van Kuijk AWR, Kruijff JWF, l'Ami MJ, Krieckaert CLM, Wolbink G.

PLoS One. 2018 Oct 9;13(10):e0205125. doi: 10.1371/journal.pone.0205125. eCollection 2018.

14.

Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

van Schie KA, Kruithof S, Ooijevaar-de Heer P, Derksen NIL, van de Bovenkamp FS, Saris A, Vidarsson G, Bentlage AEH, Jiskoot W, Romeijn S, Koning RI, Bos E, Stork EM, Koeleman CAM, Wuhrer M, Wolbink G, Rispens T.

Ann Rheum Dis. 2018 Oct;77(10):1471-1479. doi: 10.1136/annrheumdis-2018-213299. Epub 2018 Jun 26.

PMID:
29945923
15.

Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra® microsampler vs dried blood spot.

Bloem K, Schaap T, Boshuizen R, Kneepkens EL, Wolbink GJ, Vries A, Rispens T.

Bioanalysis. 2018 Jun 1;10(11):815-823. doi: 10.4155/bio-2018-0010. Epub 2018 Jun 4.

PMID:
29863412
16.

[Personalised medicine in rheumatology].

van Vollenhoven RF, L'ami M, Wolbink G.

Tijdschr Psychiatr. 2018;60(3):146-150. Review. Dutch.

17.

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

l'Ami MJ, Krieckaert CLM, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Oct;77(10):e68. doi: 10.1136/annrheumdis-2017-212602. Epub 2017 Nov 13. No abstract available.

PMID:
29133475
18.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
19.

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ.

Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.

PMID:
28939629
20.

Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases.

Kneepkens EL, Pouw MF, Wolbink GJ, Schaap T, Nurmohamed MT, de Vries A, Rispens T, Bloem K.

Br J Clin Pharmacol. 2017 Nov;83(11):2474-2484. doi: 10.1111/bcp.13371. Epub 2017 Aug 22.

21.

Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.

Ruwaard J, l'Ami MJ, Marsman AF, Kneepkens EL, van Denderen JC, van der Horst-Bruinsma IE, Nurmohamed MT, Wolbink G.

Scand J Rheumatol. 2018 Mar;47(2):122-126. doi: 10.1080/03009742.2017.1330419. Epub 2017 Jul 26.

PMID:
28745108
22.

Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.

van Schie KA, Ooijevaar-De Heer P, Kruithof S, Plasencia C, Jurado T, Pascual Salcedo D, Brandse JF, d'Haens GR, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2017 Jul;76(7):1285-1288. doi: 10.1136/annrheumdis-2016-211035. Epub 2017 Apr 28.

PMID:
28455438
23.

Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.

l'Ami MJ, Kneepkens EL, Nurmohamed MT, Krieckaert CLM, Visman IM, Wolbink GJ.

Clin Exp Rheumatol. 2017 May-Jun;35(3):431-437. Epub 2017 Jan 5.

PMID:
28079512
24.

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters.

de Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, Verweij CL.

Arthritis Res Ther. 2016 Dec 12;18(1):290.

25.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

26.

Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S.

Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966.

27.

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T.

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. No abstract available.

PMID:
27717666
28.

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange.

van Schie KA, Ooijevaar-de Heer P, Dijk L, Kruithof S, Wolbink G, Rispens T.

Sci Rep. 2016 Sep 8;6:32747. doi: 10.1038/srep32747.

29.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.

PMID:
27440258
30.

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH.

Oncologist. 2016 Oct;21(10):1260-1268. Epub 2016 Jul 20. Review.

31.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767
32.

Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required.

Moots RJ, Balsa A, Wolbink G.

Ann Rheum Dis. 2016 May;75(5):e24. doi: 10.1136/annrheumdis-2016-209178. Epub 2016 Feb 4. No abstract available.

PMID:
26847822
33.

Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies.

van Schouwenburg PA, Kruithof S, Wolbink G, Wouters D, Rispens T.

J Pharm Biomed Anal. 2016 Feb 20;120:198-201. doi: 10.1016/j.jpba.2015.12.040. Epub 2015 Dec 28.

PMID:
26748377
34.

Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.

Marsman AF, Kneepkens EL, Ruwaard J, Wei JC, Nurmohamed MT, van Denderen C, van der Horst-Bruinsma IE, Rispens T, Wolbink G.

Scand J Rheumatol. 2016 Jul;45(4):331-4. doi: 10.3109/03009742.2015.1114666. Epub 2016 Jan 4. No abstract available.

PMID:
26727457
35.

IgG Subclass Specificity Discriminates Restricted IgM Rheumatoid Factor Responses From More Mature Anti-Citrullinated Protein Antibody-Associated or Isotype-Switched IgA Responses.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Wolbink G, Rispens T.

Arthritis Rheumatol. 2015 Dec;67(12):3124-34. doi: 10.1002/art.39299.

36.

Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.

Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D.

J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15.

PMID:
26178279
37.

Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis.

Kerkman PF, Fabre E, van der Voort EI, Zaldumbide A, Rombouts Y, Rispens T, Wolbink G, Hoeben RC, Spits H, Baeten DL, Huizinga TW, Toes RE, Scherer HU.

Ann Rheum Dis. 2016 Jun;75(6):1170-6. doi: 10.1136/annrheumdis-2014-207182. Epub 2015 Jun 1.

PMID:
26034045
38.

Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

van Schie KA, Wolbink GJ, Rispens T.

MAbs. 2015;7(4):662-71. doi: 10.1080/19420862.2015.1048411. Review.

39.

Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis.

van Heemst J, Jansen DT, Polydorides S, Moustakas AK, Bax M, Feitsma AL, Bontrop-Elferink DG, Baarse M, van der Woude D, Wolbink GJ, Rispens T, Koning F, de Vries RR, Papadopoulos GK, Archontis G, Huizinga TW, Toes RE.

Nat Commun. 2015 May 5;6:6681. doi: 10.1038/ncomms7681.

PMID:
25942574
40.

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.

de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, Jansen G, Voskuyl AE, Verweij CL.

Arthritis Res Ther. 2015 Mar 23;17:78. doi: 10.1186/s13075-015-0564-y.

41.

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.

Menting SP, van den Reek JM, Baerveldt EM, de Jong EM, Prens EP, Lecluse LL, Wolbink GJ, Van der Kleij D, Spuls PI, Rispens T.

Br J Dermatol. 2015 Sep;173(3):855-7. doi: 10.1111/bjd.13834. Epub 2015 Aug 2. No abstract available.

PMID:
25865153
42.

Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Aug;74(8):e41. doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8. No abstract available.

PMID:
25854585
43.

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.

Bloem K, van Leeuwen A, Verbeek G, Nurmohamed MT, Wolbink GJ, van der Kleij D, Rispens T.

J Immunol Methods. 2015 Mar;418:29-38. doi: 10.1016/j.jim.2015.01.007. Epub 2015 Jan 27.

PMID:
25637408
44.

Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.

Rombouts Y, Willemze A, van Beers JJ, Shi J, Kerkman PF, van Toorn L, Janssen GM, Zaldumbide A, Hoeben RC, Pruijn GJ, Deelder AM, Wolbink G, Rispens T, van Veelen PA, Huizinga TW, Wuhrer M, Trouw LA, Scherer HU, Toes RE.

Ann Rheum Dis. 2016 Mar;75(3):578-85. doi: 10.1136/annrheumdis-2014-206598. Epub 2015 Jan 13.

PMID:
25587188
45.

Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs.

Vogelzang EH, Pouw MF, Nurmohamed M, Kneepkens EL, Rispens T, Wolbink GJ, Krieckaert CL.

Ann Rheum Dis. 2015 Feb;74(2):474-5. doi: 10.1136/annrheumdis-2014-206588. Epub 2014 Nov 28. No abstract available.

PMID:
25433018
46.

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23.

PMID:
25342759
47.

Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, van Buren EE, van Ham M, Aarden L, Wolbink G, Wouters D, Rispens T.

J Biol Chem. 2014 Dec 12;289(50):34482-8. doi: 10.1074/jbc.M114.615500. Epub 2014 Oct 17. Review.

48.

Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.

Kneepkens EL, Plasencia C, Krieckaert CL, Pascual-Salcedo D, van der Kleij D, Nurmohamed MT, López-Casla MT, Wieringa R, Rispens T, Wolbink G.

Ann Rheum Dis. 2014 Dec;73(12):2217-9. doi: 10.1136/annrheumdis-2014-205983. Epub 2014 Sep 26. No abstract available.

PMID:
25261580
49.

Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.

Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, Krieckaert CL.

Ann Rheum Dis. 2014 Dec;73(12):2178-82. doi: 10.1136/annrheumdis-2014-205554. Epub 2014 Aug 12.

PMID:
25115447
50.

Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies.

Suurmond J, Rivellese F, Dorjée AL, Bakker AM, Rombouts YJ, Rispens T, Wolbink G, Zaldumbide A, Hoeben RC, Huizinga TW, Toes RE.

Ann Rheum Dis. 2015 Oct;74(10):1915-23. doi: 10.1136/annrheumdis-2014-205562. Epub 2014 May 12.

PMID:
24818634

Supplemental Content

Loading ...
Support Center